Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …

Background Functional impairment of interferon, a natural antiviral component of the
immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to …

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …

Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …

The high susceptibility of humans to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection, the cause of coronavirus disease 2019 (COVID-19), reflects the novelty of …

Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …

Human parainfluenza viruses (HPIVs) are single-stranded, enveloped RNA viruses of the
Paramyoviridaie family. There are four serotypes which cause respiratory illnesses in children …

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense
RNA virus and member of the Paramyxoviridae family of the genus Pneumovirus that was first …

Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective,
breakthrough infections are occurring. Booster vaccinations have recently received emergency …